Clinical trial
A Multicenter, Randomized, Double-blind, Multiple Ascending Dose, Placebo-controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-associated Steatotic Liver Disease Complicated With Chronic Hepatitis B.
NCT07589400 is registered in ClinicalTrials.gov with Xiamen Amoytop Biotech Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Multiple Ascending Dose, Placebo-controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-associated Steatotic Liver Disease Complicated With Chronic Hepatitis B.
- Lead sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- October 30, 2026
- Completion date
- June 30, 2027
- Enrollment
- 24 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
chronic hepatitis b, metabolic dysfunction-associated steatotic liver disease